Capital World Investors Boosts Stock Position in argenx SE (NASDAQ:ARGX)

Capital World Investors lifted its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,786,936 shares of the company's stock after purchasing an additional 86,687 shares during the period. Capital World Investors owned about 2.94% of argenx worth $1,099,002,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. GeoWealth Management LLC increased its holdings in shares of argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC purchased a new position in argenx in the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC raised its holdings in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after purchasing an additional 48 shares in the last quarter. FIL Ltd purchased a new stake in shares of argenx during the 4th quarter worth approximately $38,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Stock Up 1.0 %

Shares of ARGX traded up $5.86 on Thursday, reaching $600.51. The stock had a trading volume of 269,363 shares, compared to its average volume of 308,217. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21. The firm has a market capitalization of $36.67 billion, a PE ratio of -682.40 and a beta of 0.60. The firm has a 50-day moving average of $599.54 and a 200 day moving average of $606.69.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, sell-side analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ARGX. JMP Securities upped their price objective on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. Oppenheimer raised their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Truist Financial reaffirmed a "buy" rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Wedbush reissued an "outperform" rating and set a $715.00 price target on shares of argenx in a report on Friday, April 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $699.28.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.